Rznomics to hold international symposium at Korea Microbiological Biotechnology Association.

Rznomics announced on the 20th that it will participate in the International Academic Conference of the Korea Microbiological Biotechnology Association, which will be held at the Gyeongju Hwabaek Center for three days from the 21st. The conference will be held in the form of international symposiums and regular conferences to commemorate the 50th anniversary of the conference, and it is expected to be a venue for academic exchanges to share innovative research results and latest knowledge.

Rznomics plans to co-host a session of one of the international symposiums with the academic society on the 22nd. The theme of the session is "RNA gene therapy," which is drawing attention as a state-of-the-art bio-new drug field, and consists of presentations from domestic and foreign experts such as Bruce Sullenger, Duke University professor, Dong-ki Lee, Ewha Womans University professor Hyuk-jin Lee, and Rznomics CEO Seong-wook Lee.

The first speaker, Professor Sullenger, is currently serving as vice president of the recently established International Society for RNA Therapy. The conference will present the results of preclinical and phase 1 clinical studies related to acute ischemic stroke (AIS) disease. CEO Dong-ki Lee is a professor of chemistry at Sungkyunkwan University and is developing RNA treatments based on RNA interference technology by establishing Orix based on RNA interference (RNAi) technology. Professor Hyuk-jin Lee is a professor of pharmacy at Ewha Womans University and is actively engaged in research in the field of target lipid nanoparticles.

CEO Seong-wook Lee, a professor of bio-convergence engineering at Dankook University, is a leading researcher in the field of RNA replacement enzyme technology and has been researching the field for more than 20 years to optimize the technology. Genetic treatments for rare and intractable diseases such as anticancer, degenerative and genetic diseases are being developed, and the conference will introduce RNA editing technologies based on RNA replacement enzymes and announce the development status and preclinical results.

Rznomics has an RNA replacement enzyme platform technology that can remove target RNA and simultaneously express therapeutic genes. It has secured various pipelines such as anticancer drugs, Alzheimer's, hereditary retinal biodegradation, and Rhett's syndrome, and plans to continue expanding into new intractable disease areas. Rznomics was recently introduced as a major organization related to RNA editing in the famous scientific journal Nature Biotechnology.

Seong-wook Lee, CEO of Rznomics, said, "I recently participated in conferences and business conferences such as the American Society for Gene Cell Therapy (ASGCT), the American Society for Clinical Oncology (ASCO), and BIOUS. I hope this will serve as an opportunity for international industry-academic cooperation and development."